Bone-targeted exosomes delivering betaine reverse bone loss in osteoporotic rats
The engineered delivery vehicle enhances autophagy in senescent stem cells and suppresses osteoclast activity to restore bone metabolic homeostasis.
In ovariectomized rats, researchers tested an engineered nanodelivery system designed to deliver betaine directly to bone tissue. The platform, termed BZ@Exos, combines betaine-loaded metal-organic frameworks with exosomes engineered to co-overexpress CXCR4 for bone targeting and CD47 to avoid clearance by the mononuclear phagocyte system. Once internalized, betaine binds 14-3-3 proteins to trigger TFEB nuclear translocation. This process enhanced autophagic flux in senescent bone marrow mesenchymal stem cells and promoted their osteogenic differentiation. Concurrently, the treatment inhibited osteoclast-mediated bone resorption. When administered intravenously, the therapy reversed bone loss, improved bone microstructure, and alleviated senescence-related phenotypes in the osteoporotic rats.
Why it matters
Restoring autophagic flux in senescent stem cells addresses a primary cellular driver of impaired tissue regeneration during aging. Targeting this pathway while simultaneously curbing bone resorption highlights a dual-action approach for managing age-associated metabolic bone disorders.
Caveats
The study was conducted exclusively in cell cultures and ovariectomized rat models, so the findings cannot be directly applied to human osteoporosis without clinical validation.
- Betaine
- Cellular senescence
- Disabled macroautophagy
- Stem cell exhaustion
- Autophagy
- Cd47
- Cxcr4
- Tfeb
- Ywhab
- Osteoporosis
- Rattus norvegicus
The paper
Bone-Targeted Engineered Exosomes Delivering Betaine Alleviate Osteoporosis via Autophagy-Driven Osteogenesis
Li X, Li M, Li Z et al.
Advanced Materials · 27 Sep 2026